653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma
Michael Sebag, Noopur S. Raje, Nizar J. Bahlis, et al.
Elranatamab Mono (Q1W or Q2W,) in RRMM had a manageable safety profile, exhibiting a confirmed ORR of 70 percent and a CR / sCR rate of 30 percent, with a confirmed ORR of 83 percent in RP2D. The authors consider it particularly important that elranatamab induces deep and sustained clinical responses in RRMM patients with / without prior targeted BCMA therapy. MRD evaluable patients even showed 100 percent MRD negativity. The data support continued development of elranatamab as a single agent and in combination with standard therapies.
Philippe Moreau, Saad Z. Usmani, Alfred L. Garfall, et al.
Teclistamab in the RP2D in 159 patients proved to be verifiably safe. The data also show that teclistamab monotherapy induces profound and lasting responses in heavily pretreated RRMM with a manageable safety profile.
Natalie S. Callander, Vincent Ribrag, Paul G. Richardson, et al.
Belamaf in combination with aICOS demonstrated encouraging clinical activity. The safety profile was easily manageable with dose adjustments in heavily pretreated RRMM.
Dan T. Vogl, Jonathan L. Kaufman, Sarah A. Holstein, et al.
Modakafusp alfa (TAK-573), a new candidate for the treatment of RRMM, demonstrated promising anti-myeloma activity in heavily pre-treated patients. This also applied to anti-CD38 mAb refractory patients and patients who had already received an anti-CD38 mAb.
David J. Chung, Nina Shah, Dina Stroopinsky, et al.
The investigation showed that successful site-specific production is possible. With the DC/MM fusion vaccination with lenalidomide maintenance vaccination after autoHCT, no significant increase in CR rates was achieved after 1 year, but measurable anti-MM immunoreactivity was observed. This calls for longer-term follow-up because of their effects on the duration of response.
Shaji K Kumar, Anita D'Souza, Nina Shah, et al.
TNB-383B in pts with RRMM is well tolerated with an ORR of 79% observed at doses ≥40 mg in the dose-escalation cohorts. Despite having a shorter follow-up period, this trend was also observed at doses ≥40 mg in the combined dose-escalation/expansion cohorts (ORR: 64%). Enrollment into the dose-expansion arm is ongoing; updated data will be presented at the meeting.
TNB-383B is well tolerated in patients with RRMM. Treatment achieved an ORR of 79 percent at doses ≥ 40 mg in the dose escalation cohorts. This trend was also evident at doses ≥ 40 mg in the combined dose escalation/expansion cohorts (ORR: 64%). Updated data will be presented in the oral session.